CV DEATH HAS A NEW OPPONENT
Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease
Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease
 
 

Empagliflozin (JARDIANCE)'s Consistent CV and Renal Benefits in HFrEF

Document ID: PC-PH-103702

04/07/2022

Author: Boehringer Ingelheim

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

        Related content

         
        PC-PH-103702
        Production date: July 2022